• Redx Announces RXC004 Topline Data From a Phase 2 Monotherapy Module

    Read more
  • Redx and Jounce Announce Recommended Business Combination

    Read more
  • Redx Provides Progress Update on RXC007 Clinical Programme

    Read more
  • Redx to Present at the 2nd Annual Wnt & β-Catenin Pathway Targeted Drug Development Summit

    Read more
  • Final Audited Results for the Year Ended 30 September 2022

    Read more
  • Redx Signs Clinical Trial Collaboration and Supply Agreement with MSD to evaluate RXC004 in combination with KEYTRUDA® (pembrolizumab) in PORCUPINE2 Study in Biliary Cancer

    Read more
  • Notice of Preliminary Results

    Read more
  • Redx to Present Poster on the Potential of RXC008 in Crohn’s Disease at the Inflammatory Bowel Disease Nordic Conference

    Read more
  • RXC004 Phase 2 Combination Arms to Open Enrolment

    Read more
  • Redx to Present at Jefferies London

    Read more